Trials / Unknown
UnknownNCT04646928
Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
Efficacy of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients With Compensated Cirrhosis and Low Viral Load: a Multicenter, Prospective Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 245 (estimated)
- Sponsor
- CHA University · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To analyze the incidence of liver cancer after entecavir administration among patients with low viral load and cirrhosis due to chronic hepatitis B infection.
Detailed description
To analyze the incidence of liver cancer after entecavir administration among patients with low viral load (HBV DNA titer\<2,000 IU/mL (104 copies/mL)) and cirrhosis due to chronic hepatitis B infection.
Conditions
Timeline
- Start date
- 2017-03-17
- Primary completion
- 2022-05-28
- Completion
- 2022-08-26
- First posted
- 2020-11-30
- Last updated
- 2020-11-30
Locations
11 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04646928. Inclusion in this directory is not an endorsement.